A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

Exclusion Criteria

• •Use of tobacco or nicotine-containing products within 4 weeks of Day 1 and while on study,
• •Use of a CYP3A4 inhibitor or inducer within 14 days prior to Day 1 and until Day 5,
• •Use of a warfarin-derivative anticoagulant within 14 days prior to Day 1 and until Day 5,
• •Encephalopathy \>= grade 2,
• •Significant history of cardiac disease unless well-controlled,
• •Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patient's ongoing participation,
• •Concurrent anticancer therapy or any other investigational agents within 4 weeks of Day 1 and while on study,
• •Symptomatic brain metastases that are not stable, require steroids, are potentially life-threatening, or that have required radiation within the last 4 weeks,
• •Gastro-intestinal abnormalities, including inability to take oral medication, requirement for IV alimentation, active peptic ulcer or prior surgical procedures affecting absorption.